This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansen, L. L. Articles by Kruse, T. A. Search for Related Content PubMed PubMed Citation Articles by Hansen, L. L. Articles by Kruse, T. A.

Allelic Loss of 16q23.2–24.2 Is an Independent Marker of Good Prognosis in Primary Breast Cancer¹

Institute of Human Genetics, Aarhus University (L. L. H., T. A. K.), and Department of Oncology (M. Y., J. A.) and Danish Cancer Society, Department of Experimental Clinical Oncology (J.O.), Aarhus University Hospital, DK-8000 Aarhus C, Denmark

Allelic loss, detected as a loss of heterozygosity (LOH) on the long arm of chromosome 16, is an early and frequent event in breast cancer. Despite this, the clinical significance of LOH on 16q has been very poorly studied.

In this study, corresponding blood and tumor samples from 199 clinically well-characterized primary breast cancer patients were analyzed for LOH with the highly polymorphic microsatellite marker D16S511, located at 16q23.2–24.2. 61% of 168 informative tumors showed LOH. Univariate and multivariate analysis found a highly significant association between LOH at 16q23.2–24.2 and freedom from distant metastases, disease-free survival, and overall survival, respectively. No association was found with other clinical parameters such as menopausal status, tumor size, lymph node status, histopathology, and lymph node capsule invasion.

This makes allelic loss of 16q23.2–24.2 an independent marker of good prognosis for primary breast cancer.

¹ Supported by Danish Cancer Society Grants 93-027 and 94-10054 and the Aarhus University Research Fund.

² To whom requests for reprints should be addressed, at Institute of Human Genetics, The Bartholin Building, Aarhus University, DK-8000 Aarhus C, Denmark. Phone: 45-89421680; Fax: 45-86123173; E-mail: Lotte@humgen.aau.dk.

Received 10/31/97. Accepted 3/19/98.

This article has been cited by other articles:

				L. Nakopoulou, E. G Panayotopoulou, I. Giannopoulou, I. Tsirmpa, S. Katsarou, E. Mylona, P. Alexandrou, and A. Keramopoulos Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis J. Clin. Pathol., July 1, 2007; 60(7): 808 - 815. [Abstract] [Full Text] [PDF]

				C. Gunnarsson, B. M. Olsson, and O. Stal Abnormal Expression of 17{beta}-Hydroxysteroid Dehydrogenases in Breast Cancer Predicts Late Recurrence Cancer Res., December 1, 2001; 61(23): 8448 - 8451. [Abstract] [Full Text] [PDF]

				A.-M. Cleton-Jansen, D. F. Callen, R. Seshadri, S. Goldup, B. McCallum, J. Crawford, J. A. Powell, C. Settasatian, H. van Beerendonk, E. W. Moerland, et al. Loss of Heterozygosity Mapping at Chromosome Arm 16q in 712 Breast Tumors Reveals Factors that Influence Delineation of Candidate Regions Cancer Res., February 1, 2001; 61(3): 1171 - 1177. [Abstract] [Full Text]